Alkermes (NASDAQ:ALKS) Price Target Raised to $50.00

Alkermes (NASDAQ:ALKS) had its target price boosted by HC Wainwright from $43.00 to $50.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage presently has a “neutral” rating on the stock. HC Wainwright‘s price objective suggests a potential upside of 9.43% from the stock’s previous close.

ALKS has been the topic of a number of other research reports. Piper Sandler reaffirmed an “overweight” rating and set a $65.00 price objective (up from $43.00) on shares of Alkermes in a research report on Tuesday, July 28th. Needham & Company LLC reiterated a “buy” rating and issued a $62.00 target price on shares of Alkermes in a report on Monday, September 21st. Wells Fargo & Company reissued an “overweight” rating on shares of Alkermes in a research report on Wednesday. Weiss Ratings reissued a “hold (c)” rating on shares of Alkermes in a research report on Friday, August 7th. Finally, Robert W. Baird raised their price target on shares of Alkermes from $58.00 to $61.00 and gave the company an “outperform” rating in a report on Tuesday, September 22nd. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $54.81.

Alkermes Stock Performance

Shares of NASDAQ:ALKS opened at $45.69 on Wednesday. The firm has a 50 day moving average of $43.92 and a 200 day moving average of $40.59. The company has a quick ratio of 1.85, a current ratio of 2.30 and a debt-to-equity ratio of 0.82. The company has a market capitalization of $7.66 billion, a price-to-earnings ratio of 104.39 and a beta of 0.32. Alkermes has a 52 week low of $27.00 and a 52 week high of $55.67.

Alkermes (NASDAQ:ALKS) last announced its earnings results on Tuesday, November 3rd. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.17. Alkermes had a return on equity of 4.15% and a net margin of 3.96%. The business had revenue of $480.13 million for the quarter, compared to analysts’ expectations of $463.48 million. During the same quarter last year, the firm earned $0.49 EPS. The business’s revenue for the quarter was up 21.8% on a year-over-year basis. On average, sell-side analysts predict that Alkermes will post -0.57 earnings per share for the current fiscal year.

Insider Activity at Alkermes

In other Alkermes news, EVP David Gaffin sold 2,035 shares of the firm’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $46.17, for a total value of $93,955.95. Following the completion of the transaction, the executive vice president owned 219,353 shares of the company’s stock, valued at approximately $10,127,528.01. This trade represents a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christian Nichols sold 7,576 shares of Alkermes stock in a transaction on Monday, August 17th. The stock was sold at an average price of $49.23, for a total transaction of $372,966.48. Following the sale, the senior vice president owned 102,193 shares of the company’s stock, valued at $5,030,961.39. The trade was a 6.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 22,679 shares of company stock valued at $1,070,940 in the last three months. 4.59% of the stock is owned by insiders.

Hedge Funds Weigh In On Alkermes

Several hedge funds have recently made changes to their positions in the company. Root Financial Partners LLC acquired a new stake in Alkermes during the 3rd quarter worth about $25,000. Ameritas Advisory Services LLC acquired a new position in shares of Alkermes in the second quarter valued at about $39,000. Versant Capital Management Inc increased its holdings in shares of Alkermes by 33.9% in the second quarter. Versant Capital Management Inc now owns 1,445 shares of the company’s stock valued at $76,000 after purchasing an additional 366 shares during the period. Harbor Investment Advisory LLC purchased a new position in shares of Alkermes in the second quarter worth about $82,000. Finally, C M Bidwell & Associates Ltd. purchased a new position in shares of Alkermes in the second quarter worth about $104,000. 95.21% of the stock is owned by institutional investors and hedge funds.

Alkermes News Roundup

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Third-quarter EPS was $0.09, compared with consensus expectations for a $0.08 loss, and revenue of $480.1 million exceeded the $463.5 million estimate. Revenue rose 21.8% year over year. The earnings and revenue beats may support investor confidence. Alkermes Third Quarter 2026 Financial Results
• Positive Sentiment: Alkermes reiterated its fourth-quarter proprietary net sales outlook of $400 million to $420 million and expects Phase III data for alixorexton in mid-2027. The guidance and upcoming clinical milestone give investors benchmarks and a potential catalyst. Alkermes Outlook and Alixorexton Update
• Neutral Sentiment: EVP David Gaffin sold 2,035 shares, worth about $94,000, reducing his holdings by 0.92%. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, making it less indicative of a change in his outlook. SEC Form 4
• Negative Sentiment: Despite the quarterly beat, EPS was down from $0.49 in the year-ago quarter, highlighting weaker per-share earnings compared with last year. Alkermes Q3 Earnings Metrics

About Alkermes

Alkermes plc (NASDAQ:ALKS) is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system diseases. Its research and development activities address conditions including schizophrenia, bipolar disorder, addiction, depression and other neuropsychiatric disorders.

The company’s marketed products include Vivitrol, an extended-release injectable form of naltrexone used to treat alcohol dependence and prevent relapse to opioid dependence; Aristada and Aristada Initio, long-acting injectable formulations of aripiprazole lauroxil for the treatment of schizophrenia; and Lybalvi, a combination of olanzapine and samidorphan approved for schizophrenia and bipolar I disorder in adults.

Founded in 1987, Alkermes is incorporated in Ireland and maintains its corporate headquarters in Waltham, Massachusetts.